Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Bottom Line: The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid.The effects on growth plate cartilage were visualised by toluidine blue staining.The number of circulating tumour cells was reduced in ZOL treated animals.
Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: email@example.com.Show MeSH
Related in: MedlinePlus
Mentions: As early as three days after administration there was a significant reduction in osteoclast activity in ZOL treated animals compared to control, measured by serum TRAP concentration (PBS: 7.26 U/L vs. ZOL: 3.22 U/L; p ≤ 0.01; Fig. 3A). This effect was transient and TRAP levels in the ZOL group started to increase again by day 5. The effect of the bisphosphonate on osteoclasts was further confirmed with the detection of a significant reduction in the osteoclast number on trabecular bone surfaces 3 days after ZOL injection compared to control (PBS: 4.97 vs. ZOL: 1.20; p ≤ 0.01; Fig. 3C). The osteoclast number started to normalise to control levels on day 5. We also detected an increase in osteoclast size as early as 24 h after ZOL administration when compared to mice receiving PBS, which reached significance at day 3 (PBS: 7.99 × 10− 05 mm2 vs. ZOL: 1.89 × 10− 04 mm2, p ≤ 0.001, Fig. 3F and G).
Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: firstname.lastname@example.org.